BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 19835968)

  • 1. Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation.
    Blaes AH; Cao Q; Wagner JE; Young JA; Weisdorf DJ; Brunstein CG
    Biol Blood Marrow Transplant; 2010 Feb; 16(2):287-91. PubMed ID: 19835968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation.
    Brunstein CG; Weisdorf DJ; DeFor T; Barker JN; Tolar J; van Burik JA; Wagner JE
    Blood; 2006 Oct; 108(8):2874-80. PubMed ID: 16804113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk.
    Van Besien K; Bachier-Rodriguez L; Satlin M; Brown MA; Gergis U; Guarneri D; Hsu J; Phillips AA; Mayer SA; Singh AD; Soave R; Rossi A; Small CB; Walsh TJ; Rennert H; Shore TB
    Leuk Lymphoma; 2019 Jul; 60(7):1693-1696. PubMed ID: 30741059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low dose Rituximab for pre-emptive treatment of Epstein Barr virus reactivation after allogenic hematopoietic stem cell transplantation.
    Delapierre B; Reman O; Dina J; Breuil C; Bellal M; Johnson-Ansah H; Gac AC; Damaj G; Chantepie S
    Curr Res Transl Med; 2019 Nov; 67(4):145-148. PubMed ID: 30871955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-Hematopoietic Stem Cell Transplantation Rituximab for Epstein-Barr Virus and Post-Lymphoproliferative Disorder Prophylaxis in Alemtuzumab Recipients.
    Patel C; Pasciolla M; Abramova R; Salerno D; Gomez-Arteaga A; Shore TB; Orfali N; Mayer S; Hsu J; Phillips AA; Chaekal OK; Satlin MJ; Soave R; Kodiyanplakkal RPL; Drelick A; Plate M; Besien KV
    Transplant Cell Ther; 2023 Feb; 29(2):132.e1-132.e5. PubMed ID: 36334653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamics of Epstein-Barr viral load after hematopoietic stem cell transplantation and effect of preemptive rituximab therapy.
    Raberahona M; Wackenheim C; Germi R; Carré M; Bulabois CE; Thiébaut A; Lupo J; Semenova T; Cahn JY; Morand P; Epaulard O
    Transpl Infect Dis; 2016 Dec; 18(6):889-895. PubMed ID: 27696681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation.
    Coppoletta S; Tedone E; Galano B; Soracco M; Raiola AM; Lamparelli T; Gualandi F; Bregante S; Ibatici A; di Grazia C; Dominietto A; Varaldo R; Bruno B; Frassoni F; Van Lint MT; Bacigalupo A
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):901-7. PubMed ID: 20950702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretransplant prophylactic rituximab to prevent Epstein-Barr virus (EBV) viremia in EBV-seronegative kidney transplant recipients from EBV-seropositive donors: results of a pilot study.
    Schachtner T; Reinke P
    Transpl Infect Dis; 2016 Dec; 18(6):881-888. PubMed ID: 27632022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and dynamics of Epstein-Barr virus reactivation after alemtuzumab-based conditioning for allogeneic hematopoietic stem-cell transplantation.
    Carpenter B; Haque T; Dimopoulou M; Atkinson C; Roughton M; Grace S; Denovan S; Fielding A; Kottaridis PD; Griffiths P; Mackinnon S; Emery V; Chakraverty R
    Transplantation; 2010 Sep; 90(5):564-70. PubMed ID: 20555307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases.
    Nash RA; Dansey R; Storek J; Georges GE; Bowen JD; Holmberg LA; Kraft GH; Mayes MD; McDonagh KT; Chen CS; Dipersio J; Lemaistre CF; Pavletic S; Sullivan KM; Sunderhaus J; Furst DE; McSweeney PA
    Biol Blood Marrow Transplant; 2003 Sep; 9(9):583-91. PubMed ID: 14506660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful preemptive therapy with single-dose rituximab for Epstein-Barr virus infection to prevent post-transplant lymphoproliferative disease after pediatric hematopoietic stem cell transplantation.
    Kim BK; Kang HJ; Hong KT; An HY; Choi JY; Lee JS; Park SS; Shin HY
    Transpl Infect Dis; 2019 Dec; 21(6):e13182. PubMed ID: 31556214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamics of Epstein-Barr virus on post-transplant lymphoproliferative disorders after antithymocyte globulin-conditioned allogeneic hematopoietic cell transplant.
    Lindsay J; Othman J; Yong MK; Ritchie D; Chee L; Tay K; Tio SY; Kerridge I; Fay K; Stevenson W; Arthur C; Chen SC; Kong DCM; Greenwood M; Pergam SA; Liu C; Slavin MA
    Transpl Infect Dis; 2021 Oct; 23(5):e13719. PubMed ID: 34453768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epstein-Barr virus related post-transplant lymphoproliferative disorder prevention strategies in allogeneic hematopoietic stem cell transplantation.
    Lindsay J; Yong MK; Greenwood M; Kong DCM; Chen SCA; Rawlinson W; Slavin M
    Rev Med Virol; 2020 Jul; 30(4):e2108. PubMed ID: 32301566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases.
    Styczynski J; Einsele H; Gil L; Ljungman P
    Transpl Infect Dis; 2009 Oct; 11(5):383-92. PubMed ID: 19558376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation.
    Zallio F; Primon V; Tamiazzo S; Pini M; Baraldi A; Corsetti MT; Gotta F; Bertassello C; Salvi F; Rocchetti A; Levis A
    Clin Transplant; 2013; 27(4):E491-7. PubMed ID: 23781897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preemptive management of Epstein-Barr virus reactivation after hematopoietic stem-cell transplantation.
    Ahmad I; Cau NV; Kwan J; Maaroufi Y; Meuleman N; Aoun M; Lewalle P; Martiat P; Crokaert F; Bron D
    Transplantation; 2009 Apr; 87(8):1240-5. PubMed ID: 19384173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation.
    Peric Z; Cahu X; Chevallier P; Brissot E; Malard F; Guillaume T; Delaunay J; Ayari S; Dubruille V; Le Gouill S; Mahe B; Gastinne T; Blin N; Saulquin B; Harousseau JL; Moreau P; Milpied N; Coste-Burel M; Imbert-Marcille BM; Mohty M
    Leukemia; 2011 Jun; 25(6):932-8. PubMed ID: 21350556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and risk factors of EBV reactivation after unrelated cord blood transplantation: a Eurocord and Société Française de Greffe de Moelle-Therapie Cellulaire collaborative study.
    Dumas PY; Ruggeri A; Robin M; Crotta A; Abraham J; Forcade E; Bay JO; Michallet M; Bertrand Y; Socié G; Ionescu I; Gluckman E; Milpied N; Rocha V
    Bone Marrow Transplant; 2013 Feb; 48(2):253-6. PubMed ID: 22773124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation.
    Comoli P; Basso S; Zecca M; Pagliara D; Baldanti F; Bernardo ME; Barberi W; Moretta A; Labirio M; Paulli M; Furione M; Maccario R; Locatelli F
    Am J Transplant; 2007 Jun; 7(6):1648-55. PubMed ID: 17511690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab.
    Patriarca F; Medeot M; Isola M; Battista ML; Sperotto A; Pipan C; Toffoletti E; Dozzo M; Michelutti A; Gregoraci G; Geromin A; Cerno M; Savignano C; Rinaldi C; Barbone F; Fanin R
    Transpl Infect Dis; 2013 Jun; 15(3):259-67. PubMed ID: 23405972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.